2024-06-04 14:00:07 ET
2024-06-04 14:00:07 ET
Market Wire News is a media platform, the information on this page was provided by KlickAnalytics via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...
2024-06-04 14:00:07 ET Peter Lawson from Barclays issued a price target of $35.00 for RCUS on 2024-06-04 09:49:00. The adjusted price target was set to $35.00. At the time of the announcement, RCUS was trading at $16.15. The overall price target consensus is at $42.00 wi...